Abstracts tagged "etanercept and inflammation"

Abstract Number: 2025 • 2015 ACR/ARHP Annual Meeting
Modification of Structural Lesions on Magnetic Resonance Imaging By Etanercept: A 12-Week Randomized Placebo-Controlled Trial
Walter Maksymowych¹, Stephanie Wichuk², Maxime Dougados³, Heather Jones⁴, Annette Szumski⁵, Lisa Marshall⁴, Jack F Bukowski⁶ and Robert G Lambert⁷, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology Research Lab, University of Alberta, Edmonton, AB, Canada, ³Rheumatology Department, Hôpital Cochin, Paris, France, ⁴Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁵Department of Biostatistics, Pfizer, Collegeville, PA, ⁶Clinical Affairs, Pfizer, Collegeville, PA, ⁷Department of Radiology & Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Modification of structural lesions by anti-TNF therapy has not been demonstrated in a randomized placebo (PBO)-controlled trial. The Spondyloarthritis Research Consortium of Canada (SPARCC)…
Abstract Number: 2577 • 2014 ACR/ARHP Annual Meeting
The Ankylosing Spondylitis Disease Activity Score More Closely Reflects MRI Parameters of Sacroiliitis Than the Bath Ankylosing Spondylitis Disease Activity Index in Patients with Non-Radiographic Axial Spondyloarthritis
Walter P. Maksymowych¹, S Wichuk¹, H Jones², A Szumski³, L Marshall², J Bukowski² and RG Lambert⁴, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Pfizer Inc., Collegeville, PA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Validation of clinical measures of disease in non-radiographic axial SpA (nr-axSpA) has been limited, especially using inflammatory and structural lesions on MRI as gold…
Abstract Number: 1893 • 2014 ACR/ARHP Annual Meeting
Substantial Structural Lesions on MRI in the Sacroiliac Joints of Patients with Non-Radiographic Axial Spondyloarthritis Even in the Absence of MRI Inflammation
Walter P. Maksymowych¹, S Wichuk¹, H Jones², A Szumski³, L Marshall⁴, J Bukowski⁵ and RG Lambert⁶, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., Collegeville, PA, ⁶Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Treatment of axial SpA is increasingly aimed at intervention early in the disease course before radiographic sacroiliitis has appeared and when response to treatment…
Abstract Number: 855 • 2014 ACR/ARHP Annual Meeting
Active and Structural Lesions on MRI of the Sacroiliac Joints Predict Major Clinical Responses in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Etanercept
Walter P. Maksymowych¹, S Wichuk¹, H Jones², A Szumski³, L Marshall⁴, J Bukowski⁵ and RG Lambert⁶, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., Collegeville, PA, ⁶Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Previous studies evaluating predictors of major clinical response in patients with non-radiographic axial SpA (nr-axSpA) receiving treatment with anti-TNF agents have been limited by…